JULY 5, 2016: 128–3 4 129 across the range of renal function is critical in determining the
optimal treatment for patients with atrial fibrillation (AF). Indeed, an interaction between renal …

Background: Chronic kidney disease (CKD) is a potent risk factor for both ischemic stroke
and major bleeding in patients with nonvalular atrial fibrillation (NVAF). Objective: To assess …

Objective To evaluate the relative efficacy and safety of different oral anticoagulant agents
(OACs) for patients with atrial fibrillation (AF) and chronic kidney disease (CKD). Study …

The recent State-of-the-Art Review paper by Lau et al.(1) was exceptional. I commend the
authors on presenting a timely and cogent discussion of the pros and cons of antithrombotic …

Rationale & Objective Direct oral anticoagulants (DOACs) have progressively replaced
vitamin K antagonists (VKAs) for stroke prevention in patients with nonvalvular atrial …

Background Non-vitamin K antagonist oral anticoagulants (NOACs) showed a benefit-risk
profile superior to that of warfarin in atrial fibrillation (AF) patients with mild to moderate …

Background: Because of a lack of comparative data on anticoagulant use in the advanced
chronic kidney disease (CKD) population, guidelines recommend warfarin for atrial …

Objective: A lack of clarity persists regarding the efficacy and risks associated with direct oral
anticoagulants (DOACs) in end-stage renal disease (ESRD) patients with atrial fibrillation …

Background: The Cockcroft-Gault formula is recommended to determine a renal indication
for dose reduction of dabigatran, edoxaban, and rivaroxaban. Nephrology guidelines now …

Background The effectiveness and safety of warfarin use among patients with atrial
fibrillation (AF) and reduced kidney function are uncertain. Study Design Community-based …